Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

save search

Display Week 2022 Showcasing CEO Forum and Women in Tech
Published: 2022-03-18 (Crawled : 08:00) - prnewswire.com
WISA | $9.675 8616.22% 98.85% 880K twitter stocktwits trandingview |
Electronic Technology
| | O: 0.0% H: 3.39% C: 0.0%
INTC | News | $28.155 -6.43% -7.46% 150M twitter stocktwits trandingview |
Electronic Technology
| | O: 1.17% H: 0.0% C: 0.0%

ceo women
WiSA Technologies Announces Closing of Previously Announced $7.6 Million Public Offering
Published: 2022-12-01 (Crawled : 22:00) - feed.businesswire.com
WISA | $9.675 8616.22% 98.85% 880K twitter stocktwits trandingview |
Electronic Technology
| Email alert Add to watchlist

offering
Permex Petroleum Corporation Interview to Air on Bloomberg U.S. on the RedChip Money Report®
Published: 2022-11-30 (Crawled : 13:00) - globenewswire.com
OILS | $ 0% twitter stocktwits trandingview |
n/a
| Email alert Add to watchlist
OILCD | $2.41 2786.23% twitter stocktwits trandingview |
n/a
| Email alert Add to watchlist
OILCF | $3.24 0 twitter stocktwits trandingview |
n/a
| Email alert Add to watchlist

report air corporation
Permex Petroleum Corporation Postpones Listing on NYSE American
Published: 2022-11-16 (Crawled : 13:00) - globenewswire.com
OILCF | $3.24 0 twitter stocktwits trandingview |
n/a
| Email alert Add to watchlist
OILCD | $2.41 2786.23% twitter stocktwits trandingview |
n/a
| Email alert Add to watchlist
OILS | $ 0% twitter stocktwits trandingview |
n/a
| Email alert Add to watchlist

corporation
Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Published: 2021-04-27 (Crawled : 00:00) - prnewswire.com
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 0.0% H: 10.53% C: 8.91%

therapy t-cell
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
Published: 2021-05-12 (Crawled : 22:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: -0.85% H: 3.42% C: -7.69%

financial results results therapeutics
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Published: 2021-05-20 (Crawled : 13:00) - prnewswire.com
TRIL | $18.44 0% twitter stocktwits trandingview |
Health Technology
| | O: 0.12% H: 1.97% C: -2.32%
SEEL | $0.812 -3.02% -3.12% 570K twitter stocktwits trandingview |
Health Technology
| | O: -3.36% H: 6.96% C: 4.43%
ONCY | $1.825 3.69% 3.56% 110K twitter stocktwits trandingview |
Health Technology
| | O: 4.24% H: 5.93% C: 3.73%
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: -0.42% H: 7.14% C: 5.88%
ATNX 4 | $0.1904 2.37% 2.31% 1.4M twitter stocktwits trandingview |
Health Technology
| | O: -0.2% H: 0.79% C: -5.12%

treatment cancer growth pancreatic pancreas
Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
Published: 2021-01-13 (Crawled : 15:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 8.85% H: 2.39% C: -0.48%

therapy ev t-cell
Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial
Published: 2021-01-05 (Crawled : 15:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 18.37% H: 25.86% C: -0.57%

fda trial phase 2 clinical hold
Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant
Published: 2021-03-03 (Crawled : 19:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 3.2% H: 4.26% C: 0.39%

phase 2 myeloid leukemia stem cell leukemia trial acute myeloid leukemia
Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Published: 2021-03-11 (Crawled : 22:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 0.0% H: 2.39% C: 0.8%

offering therapeutics publication
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results
Published: 2021-03-09 (Crawled : 23:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 6.81% H: 2.54% C: 0.0%

financial results results therapeutics
Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock
Published: 2021-03-16 (Crawled : 21:00) - prnewswire.com
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 0.54% H: 3.21% C: 0.53%

offering
Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Published: 2021-03-12 (Crawled : 17:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: -28.06% H: 8.24% C: 6.59%

offering
Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference
Published: 2021-03-15 (Crawled : 12:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 1.55% H: 0.0% C: -3.55%

conference
Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: -0.78% H: 4.38% C: 1.87%

conference health
Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 2.29% H: 2.41% C: -5.17%

phase 2
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas
Published: 2021-08-19 (Crawled : 00:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: -1.69% H: 3.45% C: -3.45%

cancer research granted grant
Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results
Published: 2021-08-10 (Crawled : 20:00) - prnewswire.com
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: -1.24% H: 0.76% C: -0.25%

financial results results therapeutics
Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting
Published: 2021-11-18 (Crawled : 22:00) - biospace.com/
MRKR | $3.1 778.69% 88.62% 160K twitter stocktwits trandingview |
Consumer Services
| | O: 0.0% H: 0.74% C: -7.35%

ema phase 1 t-cell
Gainers vs Losers
66% 34%

Top 10 Gainers

Your saved searches
Save your searches and get alerts when important news are released.